Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

fostamatinib

- PMLiVE

AstraZeneca’s Tezspire receives EC approval as severe asthma add-on treatment

Tezspire demonstrated superiority across every primary and key secondary endpoint compared to placebo

- PMLiVE

AstraZeneca’s COVID-19 treatment granted EC approval

Evusheld significantly reduced risk of severe COVID-19 or death in a phase 3 trial

- PMLiVE

AstraZeneca/Sanofi’s Beyfortus receives CHMP recommendation for prevention of RSV disease in infants

Beyfortus reduced the incidence of medically attended lower respiratory tract infections caused by RSV

- PMLiVE

AstraZeneca’s COVID-19 treatment receives CHMP recommendation for use in EU

Evusheld provided statistically significant protection against progression to severe COVID-19 or death

Impact of COVID-19 on the Biopsychosocial Model of Health

Dr. Tarry Ahuja, Manager of Program Development in Pharmaceutical Reviews and Senior RWE Advisor at CADTH, explores the impact of COVID-19 on the biopsychosocial model of health, key opportunities and...

Impetus Digital

- PMLiVE

AstraZeneca’s Imfinzi plus chemotherapy shows promise for advanced biliary tract cancer

Updated results from a phase 3 trial showed the combination treatment reduced the risk of death by 24% versus chemotherapy alone

- PMLiVE

AstraZeneca and Daiichi Sankyo’s Enhertu shows significant improvements for lung cancer patients

Data showed a confirmed objective response rate of 53.8% in patients with HER2-mutant metastatic non-small cell lung cancer

- PMLiVE

AstraZeneca shares positive Tagrisso data in patients with EGFR-mutated lung cancer

Lung cancer is the leading cause of cancer death among both men and women

- PMLiVE

NICE rejects AstraZeneca and MSD’s Lynparza as NHS prostate cancer treatment

The drug will not be available as a treatment option for men with prostate cancer in England and Wales

- PMLiVE

FREE Live Webinar – Overcoming Patient Recruitment Challenges in Rare Disease Trials

Innovative Trials and Pfizer invite you to attend the live webinar

Innovative Trials

- PMLiVE

AstraZeneca’s Farxiga data shows ‘significant’ mortality benefits in heart failure patients

The pre-specified pooled analysis from two phase 3 trials demonstrated a reduction in cardiovascular death by 14%

There’s No Going Back: How COVID-19 will Change Pharma Forever

Munther Baara, VP Product Strategy and Innovation at EDETEK, discusses all things clinical trials. Especially, we discuss the current gaps and the impact of COVID-19 on the way Pharma approaches...

Impetus Digital

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links